CompletedPhase 2NCT03253913

Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial

Studying Lymphangioleiomyomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Cincinnati
Principal Investigator
Nishant Gupta, MD
University of Cincinnati
Intervention
Sirolimus(drug)
Enrollment
25 enrolled
Eligibility
18 years · FEMALE
Timeline
20182022

Study locations (1)

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03253913 on ClinicalTrials.gov

Other trials for Lymphangioleiomyomatosis

Additional recruiting or active studies for the same condition.

See all trials for Lymphangioleiomyomatosis

← Back to all trials